title: [Zoledronic Acid Administration is Effective for Hematopoiesis Management in a Patient with Primary Myelofibrosis].
abstract: An 80-year-old man received a diagnosis of anemia and a decreased platelet count from his physician in 2008, and was referred to our department where primary myelofibrosis was diagnosed.The patient was classified into the lower risk group according to the International Prognostic Scoring System(IPSS), and was followed up without treatment.In June 2010, pancytopenia progressed, and the patient was reclassified into the higher risk group.Blood count did not increase with metenolone treatment, but increased with zoledronic acid(ZA)that he started receiving from January 2012. After ZA treatment, circulating levels of vascular endothelial growth factor(VEGF)and transforming growth factor-b(TGF-b)decreased, and bone marrow biopsy showed an absence of reticular fibers and collagen fibers.In the present case, we observed that the blood count increased because of ZA-induced improvements in myelofibrosis.
authors.affiliation: Dept. of Gastroenterology and Hematology/Clinical Oncology, Steel Memorial Muroran Hospital.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Sugama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Hiroto
authors.initials: H
authors.lastname: Horiguchi
authors.forename: Natsumi
authors.initials: N
authors.lastname: Yamauchi
authors.forename: Ken
authors.initials: K
authors.lastname: Sato
authors.forename: Michiko
authors.initials: M
authors.lastname: Yamada
authors.forename: Kohta
authors.initials: K
authors.lastname: Hamaguchi
authors.forename: Hajime
authors.initials: H
authors.lastname: Nakamura
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Abe
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Fujii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Maeda
authors.forename: Miri
authors.initials: M
authors.lastname: Fujita
authors.forename: Masato
authors.initials: M
authors.lastname: Koguma
authors.forename: Tetsuhiko
authors.initials: T
authors.lastname: Koguma
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
mesh_terms: D000369:Aged, 80 and over; D001706:Biopsy; D004164:Diphosphonates / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid